Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Sustained NPY signaling enables AgRP neurons to drive feeding.

Chen Y, Essner RA, Kosar S, Miller OH, Lin YC, Mesgarzadeh S, Knight ZA.

Elife. 2019 Apr 29;8. pii: e46348. doi: 10.7554/eLife.46348.

2.

A gut-to-brain signal of fluid osmolarity controls thirst satiation.

Zimmerman CA, Huey EL, Ahn JS, Beutler LR, Tan CL, Kosar S, Bai L, Chen Y, Corpuz TV, Madisen L, Zeng H, Knight ZA.

Nature. 2019 Apr;568(7750):98-102. doi: 10.1038/s41586-019-1066-x. Epub 2019 Mar 27.

PMID:
30918408
3.

Regulation of Body Temperature by the Nervous System.

Tan CL, Knight ZA.

Neuron. 2018 Apr 4;98(1):31-48. doi: 10.1016/j.neuron.2018.02.022. Review.

4.

A Spotlight on Appetite.

Beutler LR, Knight ZA.

Neuron. 2018 Feb 21;97(4):739-741. doi: 10.1016/j.neuron.2018.01.050.

5.

The Forebrain Thirst Circuit Drives Drinking through Negative Reinforcement.

Leib DE, Zimmerman CA, Poormoghaddam A, Huey EL, Ahn JS, Lin YC, Tan CL, Chen Y, Knight ZA.

Neuron. 2017 Dec 20;96(6):1272-1281.e4. doi: 10.1016/j.neuron.2017.11.041.

6.

Linking smell to metabolism and aging.

Garrison JL, Knight ZA.

Science. 2017 Nov 10;358(6364):718-719. doi: 10.1126/science.aao5474. No abstract available.

7.

Dynamics of Gut-Brain Communication Underlying Hunger.

Beutler LR, Chen Y, Ahn JS, Lin YC, Essner RA, Knight ZA.

Neuron. 2017 Oct 11;96(2):461-475.e5. doi: 10.1016/j.neuron.2017.09.043.

8.

Neural circuits underlying thirst and fluid homeostasis.

Zimmerman CA, Leib DE, Knight ZA.

Nat Rev Neurosci. 2017 Aug;18(8):459-469. doi: 10.1038/nrn.2017.71. Epub 2017 Jun 22. Review.

9.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2017 Jun 1;127(6):2438. doi: 10.1172/JCI95182. Epub 2017 Jun 1. No abstract available.

10.

Identification of preoptic sleep neurons using retrograde labelling and gene profiling.

Chung S, Weber F, Zhong P, Tan CL, Nguyen TN, Beier KT, Hörmann N, Chang WC, Zhang Z, Do JP, Yao S, Krashes MJ, Tasic B, Cetin A, Zeng H, Knight ZA, Luo L, Dan Y.

Nature. 2017 May 25;545(7655):477-481. doi: 10.1038/nature22350. Epub 2017 May 17.

11.

Thirst.

Leib DE, Zimmerman CA, Knight ZA.

Curr Biol. 2016 Dec 19;26(24):R1260-R1265. doi: 10.1016/j.cub.2016.11.019.

12.

Warm-Sensitive Neurons that Control Body Temperature.

Tan CL, Cooke EK, Leib DE, Lin YC, Daly GE, Zimmerman CA, Knight ZA.

Cell. 2016 Sep 22;167(1):47-59.e15. doi: 10.1016/j.cell.2016.08.028. Epub 2016 Sep 8.

13.

Rapid Sensing of Dietary Amino Acid Deficiency Does Not Require GCN2.

Leib DE, Knight ZA.

Cell Rep. 2016 Aug 23;16(8):2051-2052. doi: 10.1016/j.celrep.2016.08.022. No abstract available.

14.

Hunger neurons drive feeding through a sustained, positive reinforcement signal.

Chen Y, Lin YC, Zimmerman CA, Essner RA, Knight ZA.

Elife. 2016 Aug 24;5. pii: e18640. doi: 10.7554/eLife.18640.

15.

Thirst neurons anticipate the homeostatic consequences of eating and drinking.

Zimmerman CA, Lin YC, Leib DE, Guo L, Huey EL, Daly GE, Chen Y, Knight ZA.

Nature. 2016 Sep 29;537(7622):680-684. doi: 10.1038/nature18950. Epub 2016 Aug 3.

16.

Making sense of the sensory regulation of hunger neurons.

Chen Y, Knight ZA.

Bioessays. 2016 Apr;38(4):316-24. doi: 10.1002/bies.201500167. Epub 2016 Feb 22. Review.

17.

Re-examination of Dietary Amino Acid Sensing Reveals a GCN2-Independent Mechanism.

Leib DE, Knight ZA.

Cell Rep. 2015 Nov 10;13(6):1081-1089. doi: 10.1016/j.celrep.2015.09.055. Epub 2015 Oct 29.

18.

Sensory detection of food rapidly modulates arcuate feeding circuits.

Chen Y, Lin YC, Kuo TW, Knight ZA.

Cell. 2015 Feb 26;160(5):829-841. doi: 10.1016/j.cell.2015.01.033. Epub 2015 Feb 19.

19.

Ablation of AgRP neurons impairs adaption to restricted feeding.

Tan K, Knight ZA, Friedman JM.

Mol Metab. 2014 Jul 10;3(7):694-704. doi: 10.1016/j.molmet.2014.07.002. eCollection 2014 Oct.

20.

A critical role for mTORC1 in erythropoiesis and anemia.

Knight ZA, Schmidt SF, Birsoy K, Tan K, Friedman JM.

Elife. 2014 Sep 8;3:e01913. doi: 10.7554/eLife.01913.

21.

Molecular profiling of neurons based on connectivity.

Ekstrand MI, Nectow AR, Knight ZA, Latcha KN, Pomeranz LE, Friedman JM.

Cell. 2014 May 22;157(5):1230-42. doi: 10.1016/j.cell.2014.03.059.

22.

Molecular profiling of activated neurons by phosphorylated ribosome capture.

Knight ZA, Tan K, Birsoy K, Schmidt S, Garrison JL, Wysocki RW, Emiliano A, Ekstrand MI, Friedman JM.

Cell. 2012 Nov 21;151(5):1126-37. doi: 10.1016/j.cell.2012.10.039.

23.

For a PDK1 inhibitor, the substrate matters.

Knight ZA.

Biochem J. 2011 Jan 15;433(2):e1-2. doi: 10.1042/BJ20102038.

PMID:
21175429
24.

Hyperleptinemia is required for the development of leptin resistance.

Knight ZA, Hannan KS, Greenberg ML, Friedman JM.

PLoS One. 2010 Jun 29;5(6):e11376. doi: 10.1371/journal.pone.0011376.

25.

Small molecule inhibitors of the PI3-kinase family.

Knight ZA.

Curr Top Microbiol Immunol. 2010;347:263-78. doi: 10.1007/82_2010_44. Review.

PMID:
20473788
26.

Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.

Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, Shokat KM.

Chem Biol. 2010 Feb 26;17(2):123-34. doi: 10.1016/j.chembiol.2010.01.010.

27.

Targeting the cancer kinome through polypharmacology.

Knight ZA, Lin H, Shokat KM.

Nat Rev Cancer. 2010 Feb;10(2):130-7. doi: 10.1038/nrc2787. Review.

28.

Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA.

Blood. 2009 May 28;113(22):5549-57. doi: 10.1182/blood-2008-06-165068. Epub 2009 Mar 24.

29.

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM.

PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.

30.

EGFR signals to mTOR through PKC and independently of Akt in glioma.

Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA.

Sci Signal. 2009 Jan 27;2(55):ra4. doi: 10.1126/scisignal.2000014. Erratum in: Sci Signal. 2009;2(60):er4.

31.

Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.

Zhang TT, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, Shokat KM, Vanhaesebroeck B, Marshall AJ.

J Allergy Clin Immunol. 2008 Oct;122(4):811-819.e2. doi: 10.1016/j.jaci.2008.08.008.

PMID:
19014771
32.

Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.

Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S.

Cancer Res. 2008 Oct 15;68(20):8361-8. doi: 10.1158/0008-5472.CAN-08-0878.

33.

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.

Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.

Nat Chem Biol. 2008 Nov;4(11):691-9. doi: 10.1038/nchembio.117. Epub 2008 Oct 12.

34.

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F.

Cancer Res. 2008 Oct 1;68(19):8127-36. doi: 10.1158/0008-5472.CAN-08-0755.

35.

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA.

J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. Erratum in: J Clin Invest. 2017 Jun 1;127(6):2438.

36.

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.

Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM.

Cancer Cell. 2008 Aug 12;14(2):180-92. doi: 10.1016/j.ccr.2008.06.014.

37.

Activity of the p110-alpha subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport.

Wang J, Knight ZA, Fiedler D, Williams O, Shokat KM, Pearce D.

Am J Physiol Renal Physiol. 2008 Sep;295(3):F843-50. doi: 10.1152/ajprenal.90348.2008. Epub 2008 Jul 23.

38.

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.

Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.

Leukemia. 2008 Sep;22(9):1698-706. doi: 10.1038/leu.2008.144. Epub 2008 Jun 12.

PMID:
18548104
39.

T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.

Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, Knight ZA, Cobb BS, Cantrell D, O'Connor E, Shokat KM, Fisher AG, Merkenschlager M.

Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7797-802. doi: 10.1073/pnas.0800928105. Epub 2008 May 28.

40.

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D.

Biochem J. 2008 Oct 1;415(1):97-110. doi: 10.1042/BJ20080639.

41.

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.

Chen JS, Zhou LJ, Entin-Meer M, Yang X, Donker M, Knight ZA, Weiss W, Shokat KM, Haas-Kogan D, Stokoe D.

Mol Cancer Ther. 2008 Apr;7(4):841-50. doi: 10.1158/1535-7163.MCT-07-0393.

42.

Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling.

Balla A, Tuymetova G, Toth B, Szentpetery Z, Zhao X, Knight ZA, Shokat K, Steinbach PJ, Balla T.

Biochemistry. 2008 Feb 12;47(6):1599-607. doi: 10.1021/bi7017927. Epub 2008 Jan 19.

PMID:
18205404
43.

HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I.

Hung CH, Thomas L, Ruby CE, Atkins KM, Morris NP, Knight ZA, Scholz I, Barklis E, Weinberg AD, Shokat KM, Thomas G.

Cell Host Microbe. 2007 Apr 19;1(2):121-33.

44.

A membrane capture assay for lipid kinase activity.

Knight ZA, Feldman ME, Balla A, Balla T, Shokat KM.

Nat Protoc. 2007;2(10):2459-66.

45.

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.

Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA.

Cancer Res. 2007 Sep 1;67(17):7960-5.

46.

A remodelled protease that cleaves phosphotyrosine substrates.

Knight ZA, Garrison JL, Chan K, King DS, Shokat KM.

J Am Chem Soc. 2007 Sep 26;129(38):11672-3. Epub 2007 Sep 6. No abstract available.

47.

Chemically targeting the PI3K family.

Knight ZA, Shokat KM.

Biochem Soc Trans. 2007 Apr;35(Pt 2):245-9.

PMID:
17371250
48.

Chemical genetics: where genetics and pharmacology meet.

Knight ZA, Shokat KM.

Cell. 2007 Feb 9;128(3):425-30.

49.

Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi.

Tóth B, Balla A, Ma H, Knight ZA, Shokat KM, Balla T.

J Biol Chem. 2006 Nov 24;281(47):36369-77. Epub 2006 Sep 26.

50.

To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front.

Van Keymeulen A, Wong K, Knight ZA, Govaerts C, Hahn KM, Shokat KM, Bourne HR.

J Cell Biol. 2006 Jul 31;174(3):437-45. Epub 2006 Jul 24.

Supplemental Content

Loading ...
Support Center